A Phase I Open Label, Multicenter, Dose-Escalation, Multidose Study of MDX-1411 Administered Every 14 days in Subjects with Advanced or Recurrent Clear Cell Renal Carcinoma (Medarex Inc. MDX1411-01).
Phase of Trial: Phase I
Latest Information Update: 13 May 2013
At a glance
- Drugs MDX 1411 (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Pharmacokinetics
- 03 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2009 Planned number of patients changed from 40 to 41 as reported by ClinicalTrials.gov.
- 01 Jul 2009 Planned end date changed from 1 Sep 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.